Eli Lilly and Company has announced the launch of Lilly TuneLab, an artificial intelligence and machine-learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on Lilly’s research data.  

Lilly estimates that this first release of AI models includes proprietary data obtained at a cost of over $1 billion. Lilly TuneLab is powered by Lilly’s full drug disposition, safety, and preclinical datasets representing experimental data obtained with hundreds of thousands of unique molecules, according to information from Lilly. In return for access, selected biotech partners contribute training data. The platform is hosted by a third-party and employs federated learning, a privacy-preserving approach that enables biotechs to tap into Lilly’s AI models without directly exposing their proprietary data or Lilly’s.  

Lilly TuneLab was developed through partnerships with global technology providers and AI/ML experts. Lilly intends to extend the platform’s features and capabilities beyond this first release, including adding in vivo small molecule predictive models. 

Lilly TuneLab is the newest addition to Lilly Catalyze360’s set of offerings for Lilly’s biotech partners, which includes strategic capital through Lilly Ventures, laboratory facilities at Lilly Gateway Labs, and drug-development expertise via Lilly ExploR&D. 

Source: Eli Lilly and Company